Yahoo Finance

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and ...

SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Yahoo Finance

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference ...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
ascopubs.org

First report of ROR2 directed therapy with a conditionally active antibody drug conjugate in advanced melanoma.

Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors. Efficacy and safety of ozuriftamab ...
Science Daily

Darwin’s short-beak enigma solved

Biologists discovered that a mutation in the ROR2 gene is linked to beak size reduction in numerous breeds of domestic pigeons. Surprisingly, different mutations in ROR2 also underlie a human disorder ...
Queen Mary University of London

ROR2 blockade as a therapy for osteoarthritis

What is new about the study? Throughout life we all develop lesions in the cartilage. For many people, especially after a certain age, cartilage loss becomes so bad that the bones grind against each ...